Purpose: High-grade serous ovarian cancer (HGSOC) is an aggressive disease with few available targeted therapies. Despite high expression of estrogen receptor-alpha (ERa) in approximately 80% of HGSOC and some small but promising clinical trials of endocrine therapy, ERa has been understudied as a target in this disease. We sought to identify hormone-responsive, ERa-dependent HGSOC.
Introduction
High-grade serous ovarian cancer (HGSOC) is an aggressive and often lethal disease with limited options for therapy. HGSOC typically responds to surgical debulking and platinum-based chemotherapy as first-line treatment but the majority of patients relapse and ultimately succumb to the disease (1) . Identifying targeted, individualized treatment strategies for ovarian cancer will be essential for improving patient survival.
One promising but understudied therapeutic target for HGSOC is estrogen receptor-alpha (ERa). ERa is expressed in approximately 80% of HGSOC (2) (3) (4) , and estrogen exposure (e.g., oral contraceptive use, hormone replacement therapy) affects the risk of ovarian cancer (4) (5) (6) . Preclinical studies have shown that estrogen can promote proliferation and migration of HGSOC cell lines and mouse models and, in part, these effects are blocked by antiestrogens (7) (8) (9) (10) (11) (12) .
Several clinical trials have evaluated endocrine therapy in ovarian cancer. Trials were small (n ¼ 14-105 patients), patients were heavily pretreated with chemotherapy, and ERa status was infrequently used as an inclusion criterion (4) . Nevertheless, in each trial, a subset of patients benefited from tamoxifen ($20% of patients; refs. [13] [14] [15] [16] [17] [18] [19] [20] , aromatase inhibitors ($17%; refs. [21] [22] [23] [24] , or fulvestrant ($40%; ref. 25) . Although consistent inclusion of ERa status may improve response rates, superior biomarkers for ERa function and endocrine responsiveness are needed.
We sought to identify HGSOC likely to be ERa-dependent and endocrine responsive. Therefore, we comprehensively characterized estrogen and antiestrogen response with regards to growth, survival, and gene expression in HGSOC cell lines and patient-derived xenograft (PDX) explants. On the basis of these data, we built an assay for endocrine response and profiled tumors from patients with ovarian cancer who received endocrine therapy to identify genes associated with clinical response. Here we show that ERa H-score with expression of other biomarkers (e.g., IGFBP3) can identify patients with HGSOC who benefit from endocrine therapy.
Materials and Methods
Antibodies and reagents Chemicals. Estradiol (E2; Sigma-Aldrich), 4-hydroxytamoxifen (4OHT; Sigma-Aldrich), ICI 182,780 (fulvestrant; Tocris Bioscience), staurosporine (STS; Tocris Bioscience), and Z-VAD (Tocris Bioscience). E2, 4OHT, and fulvestrant were solubilized in 200-proof ethanol prior to use. STS and Z-VAD were solubilized in sterile DMSO.
Antibodies. ERa 6F11 clone (Leica Biosystems), ER (SP1 Clone, Biocare Medical), bromodeoxyuridine (BrdUrd; Bu20a clone, Cell Signaling Technology), Ki67 (M1B clone, Dako), Tubulin (Sigma-Aldrich), and b-actin (Sigma-Aldrich).
Cell lines and culture conditions
PEO1, PEO4, OVSAHO, and MCF-7 cells were maintained in DMEM (Invitrogen) þ 10% FBS (Gibco). OVCA432 cells were maintained in RPMI1640 þ 10% FBS. Cell line identity was verified by short tandem repeat (STR) profiling. PEO1 and PEO4 cells were derived from the same patient (26) , PEO1 after her first recurrence and PEO4 after the tumor became platinum-resistant.
Hormone deprivation was performed as described previously (27) using IMEM þ 10% charcoal-stripped serum (CSS) for PEO1, PEO4, and OVCA432 or 5% CSS for MCF-7 and OVSAHO. Unless otherwise specified, hormones were used at the following concentrations: 1 nmol/L E2, 1 mmol/L fulvestrant, and 1 mmol/L 4OHT.
For standard (two-dimensional; 2D) proliferation assays, growth was analyzed using the FluoReporter dsDNA quantitation kit (Molecular Probes) as described previously (27) . Cells (2,000-4,000/well) were seeded in 96-well plates (Thermo Fisher Scientific). After cells adhered (16-24 hours), drug was added directly to the wells. For ultra-low attachment (ULA) assays, cells (5,000-10,000/well) were treated at the time of seeding in ULA (Corning). Viability was measured using the CellTiter-Glo assay and apoptosis with the CaspaseGlo-3/7 assay (Promega). For three-dimensional (3D) assays, dishes were coated with phenol red-free Matrigel (BD Biosciences). Cells were seeded on top of the Matrigel in media þ 2% Matrigel.
Cell line gene expression analyses
Hormone-deprived cells were treated in biological quadruplicate with vehicle, E2, 4OHT AE E2, or fulvestrant AE E2 as described previously (27) . RNA was isolated using the Illustra RNAspin Mini Kit (GE Healthcare). Gene expression was measured on Affymetrix U133A 2.0 arrays. Data were RMA normalized using the affy() package in R (command "rma()", http:// www.bioconductor.org/). Differentially expressed genes were identified with limma. When genes were represented by multiple probes, the probe with greatest variation (largest dynamic range) across samples was chosen for downstream analysis. Heatmaps were generated using the Multiple Experiment Viewer (MeV, http://www.tm4.org/). E2-regulated genes were considered "blocked" by fulvestrant or 4OHT whether E2 produced significant (P < 0.001) changes in expression compared with vehicle but fulvestrant þ E2 or 4OHT þ E2 did not. To determine overlap with E2-regulated genes in breast cancer, MCF-7 data were obtained from the GEMS database. Significantly E2-regulated genes were defined as those with q < 0.05. Because the treatment for our microarray studies was 3 hours, we used only the "early" (3-to 4-hour E2 treatment) GEMS dataset.
cDNA conversion and qRT-PCR were performed using iScript and Universal SYBR RT Supermix (Bio-Rad). Primer sequences are in Table 1 .
Immunoblotting
Cells were lysed in RIPA buffer þ Halt Phosphatase/Protease Inhibitor Cocktail (Pierce). Protein (20 mg) was run on a 10% SDS polyacrylamide gel and transferred to a polyvinylidene difluoride Table 1 . Primer sequences for qPCR
Translational Relevance
High-grade serous ovarian cancer (HGSOC) is a malignancy with extremely poor prognosis and limited therapeutic options. Targeting estrogen receptor-alpha (ERa) has shown promise in laboratory models and in clinical trials, but identification of the appropriate patient subset has remained elusive. We characterized endocrine response in cell line and patient-derived HGSOC models to identify features associated with estrogen-responsive HGSOC. In these studies, we observed that a subset of HGSOC models require estrogen for growth and survival. Furthermore, we identified genes (e.g., the ER-a target IGBP3) which were associated with clinical endocrine response. We also determined that fulvestrant may be more effective than tamoxifen at blocking cell proliferation in HGSOC. Our data may enable the identification of patients with ovarian cancer who would benefit from endocrine therapy.
membrane. Membranes were incubated with primary antibody overnight at 4 C. Blots were imaged on the Olympus LI-COR system. Antibody dilutions were as follows: ER 6F11, 1:500; Tubulin, 1:10,000.
Xenograft studies
All animal studies were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. C.B.17/ IcrHsd-Prkdc scid Lyst bg-J (SCID/Beige, Harlan Laboratories) mice were used for all studies. For PEO4 xenografts, mice underwent ovariectomy followed by subcutaneous pellet implantation (placebo or 0.03 mg E2, Innovative Research of America). Each group had n ¼ 5 mice. Two weeks after surgery, 10 6 PEO4 cells in 1:1 RPMI þ Matrigel were injected intraperitoneally (i.p.). Mice were monitored for 11 weeks after injection and then sacrificed. Tumors were harvested immediately after euthanasia. Tissue was either flash frozen in liquid nitrogen or fixed in 10% NBF. Patientderived xenografts (PDX) were provided by Dr. Paul Haluska and processed as described previously (28) . Tissue was collected at necropsy in the same manner as the PEO4 xenografts.
Explants
PDXs were passaged <5 times prior to use. PDXs were cultured ex vivo using an established protocol for primary tumors (29) . Briefly, fresh PDX tissue was harvested and dissected into approximately 1-mm 3 fragments. Fragments were cultured on VetSPON sponges (Henry Schein) partially submerged in media (IMEM þ 5% FBS þ 10 mg/mL insulin þ 10 mg/mL hydrocortisone) þ vehicle, fulvestrant, or 4OHT. Three tissue fragments were placed on each sponge. After three days, explants were pulsed with 30 mg/mL BrdUrd (Invitrogen) for 4-6 hours. Tissue was either fixed in 10% neutral-buffered formalin (NBF) for IHC or snap-frozen in liquid nitrogen. Snap-frozen tissue was processed using the RNEasy Mini Kit (Qiagen). qRT-PCR was performed as described above. IHC details are provided below. For PH045, PH053, and PH070, two sponges per treatment group (6 explant pieces total) were used for each assay type (i.e., two sponges for RNA collection and two for fixation/IHC). For PH242, only one sponge (three fragments) was used per treatment group although several time points (day 1-3) were assessed. Each tissue fragment was treated as a unique biological replicate.
IHC
Antigen retrieval was performed in citrate buffer (pH 6) for 30 minutes using a boiling water bath. Sections were then blocked in 5% BSA in PBS þ 0.5% Tween-20 for 1 hour at room temperature. Sections were incubated in primary antibody overnight at 4 C. Staining was visualized with DAB. Slides were counterstained with hematoxylin. BrdUrd staining was quantified by determining %BrdUrd þ cells (# BrdUrd þ cells/ total cells Â 100%) for a given field of view. For each treatment group, 10 fields of view were counted, spanning multiple explant pieces. IHC of clinical samples was performed by the research histology core at University of Pittsburgh Medical Center (Pittsburgh, PA). Antigen retrieval was performed in citrate buffer (pH 6) at 120 C. Staining was detected using Envision Dual Linkþ HRP Polymer and DAB (Dako). Hematoxylin was used for counterstaining. Antibody dilutions were as follows: ER 6F11, 1:50; BrdUrd, 1:200; Ki67, 1:300, ER SP-1, predilute.
Clinical samples
Paraffin-embedded tumor samples from the University of Pittsburgh Medical Center, Fox Chase Cancer Center, Roswell Park Cancer Institute, and the University of Michigan were centrally reviewed by a pathologist (E. Elishaev) to confirm >50% tumor and >50% viable cells. RNA was isolated using the AllPrep FFPE kit (Qiagen). Expression of genes on the EndoRx panel (see Materials and Methods, Supplementary File S1) was measured on the NanoString nCounter as described previously (30) . Data were normalized to internal controls and the geometric mean of four housekeeping genes. All work was approved by local Institutional Review Boards.
Design of the EndoRx assay
To develop a comprehensive assay for estrogen response, we overlapped our microarray results with publicly available preclinical studies of E2 response in breast, bone, ovarian, and endometrial cancer, and with genes differentially expressed between ERa-positive and ERa-negative breast and ovarian tumors and genes specific to "hormonally responsive" endometrial tumors from The Cancer Genome Atlas (TCGA; refs. [31] [32] [33] . Ad hoc additions were made including mediators of ERa signaling (e.g., NCOAs), genes with known associations to endocrine resistance, immune response, or tumor-stromal interactions, and genes that correlated with response in clinical trials of endocrine therapy (34, 35) .The final assay comprised 350 genes (Supplementary File S1).
Statistical analysis
Significance was determined at P ¼ 0.05 unless otherwise specified. Unpaired, two-tailed t tests were used to compare two groups. For three or more groups, one-way ANOVA and Tukey post hoc test were used. Growth curves in ULA were fit with simple logarithmic regression [log(y)¼log(y 0 )þk Ã x] and k was compared between groups using sum-of-squares F test. c 2 test was used to compute significance of overlap in E2-regulated genes between cell lines. On figures, asterisks indicate significance: ÃÃÃÃ , P < 0.0001; ÃÃÃ , P < 0.001; ÃÃ , P < 0.01; Ã , P < 0.05. Clinical specimens were dichotomized by time on endocrine therapy: "long" (!120 days, n ¼ 43) and "short" (<120 days. n ¼ 25). Differentially expressed genes were identified with edgeR; significance was determined using a likelihood ratio test and Benjamini-Hochberg correction for multiple comparisons. To construct a prediction model for classifying patients by time on endocrine therapy, support vector machines (SVM) with linear kernel was used. SVM is a supervised machine learning algorithm used to solve classification problems. It is a generalization of the maximal margin classifier. Given a separation of the hyperplane and when data are separable, the maximal margin is defined as the minimum distance of the objects to the hyperplane. In addition, we applied an SVM-RFE (Recursive Feature Extraction) to return a ranking of the features of our classification problem by training an SVM with a linear kernel and removing the feature with the smallest ranking criterion. Model accuracy was assessed through leave-one-out cross-validation. Log-rank test was used to determine significance level of the survival curves. ANOVA was used to test differences of cohort means from major clinical variables. Differences in preand postendocrine therapy CA-125 levels were determined by paired t test.
Results

Endocrine response in HGSOC cell lines
To determine whether estrogen regulates growth, we evaluated ERa expression and response to E2, fulvestrant, and 4OHT in four ERa þ HGSOC cell lines. PEO1, PEO4, and OVCA432 cells expressed high ERa but expression in OVSAHO cells was lower (Fig. 1A) ; all lines were ERb-negative (data not shown). In 2D assays, E2 stimulated proliferation of PEO4 and PEO1 cells in a dose-dependent manner, which was abrogated by fulvestrant and 4OHT. In contrast, E2 had no effect on growth of OVCA432 and OVSAHO cells (Fig. 1B) .
As ERa status alone did not predict E2 response in HGSOC cells, we examined markers of ERa function. Previous efforts to identify ERa target genes in HGSOC are limited (7, 9) . To create a comprehensive picture of the ERa transcriptome, we performed whole-genome microarrays in PEO4 and PEO1 cells after treatment with E2 AE fulvestrant or 4OHT. E2 regulated the expression of 221 and 291 genes in PEO1 and PEO4, respectively ( Fig. 1C;  Supplementary File S2) . Notably, fulvestrant was more effective than 4OHT at blocking E2 effects; 4OHT mitigated E2-mediated expression of 70% of genes in PEO4 cells and 89% in PEO1 cells, whereas fulvestrant mitigated 96% and 99.5%. There was significant overlap among E2-regulated genes in HGSOC lines (n ¼ 175/515, P < 0.001) versus MCF-7 cells (ref. 36 ; Fig. 1D ), including canonical ERa targets GREB1, CCNG2, and MYC. We validated E2-regulation (and blockade by fulvestrant and 4OHT) of GREB1, CCNG2, and MYC by qRT-PCR in PEO1 and PEO4 cells (Fig. 1E) . This suggests ERa targets in HGSOC cells comprise a largely classical E2 response.
We then evaluated endocrine response of HGSOC cells lines in models mimicking in vivo tumor growth, first via 3D growth in a Matrigel. Similar to growth in 2D, E2 increased spheroid formation in PEO4 cells ( Fig. 2A) but not in OVCA432 cells. To model ascites, a common clinical manifestation in late-stage HGSOC, we grew cells in forced suspension using ultra-low attachment (ULA) plastics. Cells in ULA grow in aggregates ( Supplementary Fig. S1A ). E2 significantly increased PEO1 and PEO4 cell number; OVSAHO and OVCA432 cells gained E2 responsiveness, as E2 now increased cell number (Fig. 2B) . ULA increased ERa mRNA and protein levels versus 2D conditions ( Fig. 2C and D) , which may mediate the novel E2 response. The effect of E2 on PEO1 appeared to be more through a decrease of cell death than increased proliferation. Survival in ULA/ forced suspension typically requires resistance to anoikis (apoptosis due to detachment) but we observed no effect of E2 on caspase-3/7 activity ( Supplementary Fig. S1B ), suggesting E2 did not inhibit anoikis but may mediate other survival mechanisms. We then sought to directly assess estrogen response in vivo. Because PEO4 displayed hormone dependence across all three culture methods, we chose this cell line for our xenograft experiments. E2 treatment increased tumor burden versus placebo (Fig. 2E) and induced GREB1 and MYC expression, consistent with our in vitro results. Taken together, these data demonstrate that some HGSOC cells are E2-responsive but that response may be dependent on 3D context.
Antiestrogen response in HGSOC explants
To examine antiestrogen response in models more closely mimicking clinical HGSOC, we utilized four PDXs that recapitulate classic ovarian cancer phenotypes. They were established from HGSOC tumors of advanced stage (III/IV) and grade (III/IV). Our models also capture the varying ERa expression of HGSOC, encompassing high (PH045), medium (PH053, PH242), and low expression (PH070 ; Fig. 3A) ; none expressed ERb (data not shown). However, HGSOC PDXs often take months to form detectable tumors (28, 37) , limiting the feasibility of large-scale in vivo studies. We therefore assessed proliferation (BrdUrd incorporation) and gene expression in PDX explants (29) following endocrine treatment (Fig. 3B) .
Treatment of PH045 explants with 4OHT significantly decreased proliferation ( Fig. 3C and D ; P ¼ 0.014, median change of À50%); 4OHT also decreased GREB1 and PGR expression and induced the E2-repressed gene CCNG2 (Fig. 3E) . 4OHT did not affect MYC expression as was observed in cell lines (data not shown). Fulvestrant produced similar but more pronounced effects; the median change in proliferation was À50% (P ¼ 0.005) but the maximal decrease was greater (À95% vs. À58%). Fulvestrant decreased ERa protein (mean change À55%), consistent with its mechanism of action, and produced stronger effects on gene expression versus 4OHT. Similar observations were made in PH053 explants (Fig. 3F-H) ; fulvestrant significantly decreased proliferation (P ¼ 0.0049) while effects of 4OHT on proliferation and gene expression were weaker. In contrast, fulvestrant did not affect PH070 and PH242 explants ( Supplementary Fig. S2 ). Lack of fulvestrant response was expected for PH070 (low/absent ERa) but PH242 had ERa levels similar to PH053. The fulvestrant resistance in PH242 thus supports clinical observations that ERa itself is limited as a biomarker of endocrine response in HGSOC (25, 34, 38, 39) . Therefore, though some Endocrine response in 3D, ULA, and cell line xenografts. A, PEO4 and OVCA432 cells were plated in Matrigel, treated as indicated, and allowed to grow for 10 days. Images are representative of two biological replicates. B, Hormone-deprived cells were plated in ULA AE E2. Data are presented as blank-corrected luminescence (mean of six replicates AE SD). Graphs are representative of three experiments. C and D, Cells were plated in 2D or ULA plates for 24 hours. ESR1 mRNA levels were measured by qRT-PCR (C) and ERa protein levels measured by immunoblot (D). Numbers below the band indicate ERa/tubulin ratio. E, PEO4 cells were injected intraperitoneally into mice after ovariectomy (OVX) plus placebo or E2 pellet supplementation. Tumor burden was measured after 11 weeks and calculated as (tumor weight/total body weight) Â 100%. Each point represents an individual mouse. F, Gene expression in xenografts was measured by qRT-PCR. Each point represents an individual mouse. Differences were not statistically significant. HGSOC PDXs are endocrine responsive, additional biomarkers are necessary to differentiate response versus resistance.
Genes associated with clinical endocrine response
To identify novel biomarkers of endocrine response, tumor specimens were procured from 70 patients with ovarian cancer who received tamoxifen and/or an aromatase inhibitor (AI) at four medical centers (Table 2) . Median age at diagnosis was 63 and the majority (85%) of patients presented at late stages (III/IV). No patient or tumor characteristics differed across centers except age; RPCI patients were significantly older (P ¼ 0.0013). There were also no significant differences in overall survival (time from diagnosis to death) or duration of endocrine therapy across cohorts ( Supplementary Fig. S3 ).
Endocrine therapy was given after chemotherapy, often in the setting of recurrent disease (Fig. 4A) . While data on disease progression after endocrine therapy were limited, we have single values posttreatment CA-125 measurements for 45 of 70 patients and these were significantly higher than pretreatment levels (P ¼ 0.031; Supplementary File S3). However, in light of the heterogeneity in our patient population (patients were placed on endocrine therapy at various points in their disease course and treated at different institutions) and to also capture patients who achieved disease stability, we chose to use time on endocrine therapy as a surrogate for clinical response.
ERa status (positive vs. negative) was not associated with response (data not shown), so we examined whether ERa levels as a continuous variable or biomarkers of ERa function were predictive of time on endocrine therapy in our cohort. ERa Hscores ranged from 0 to 270 (median ¼ 60; Fig. 4B) . Patients with an H-score >60 stayed on endocrine therapy longer, suggesting a higher likelihood of response (P ¼ 0.002; Fig. 4C ). In parallel, we evaluated expression of ERa target genes (EndoRx panel, Supplementary Fig. S4A ). This gene set (n ¼ 350) includes ERa targets identified using public data on E2 treatment in hormone-responsive cancers (n ¼ 207) and genes with known roles in antiestrogen resistance and ERa function (n ¼ 77) or the tumor microenvironment (n ¼ 66). The ERa target subset was validated in silico using public data from breast tumors [METABRIC (40) and Van't Veer and colleagues (41)], where it distinguished ERa-positive and -negative disease ( Supplementary Fig. S5A ), and in vitro using PEO4 and MCF-7 cells (Supplementary Fig. S5B) .
We compared expression of the EndoRx panel between patients with a long (!4 months) or short (<4 months) duration of endocrine therapy. We specifically chose 4 months for a cutoff to allow adequate time to achieve disease stability or response with oral hormonal agents, which are often slower to affect tumor growth than cytotoxic therapies. Among the top 11 genes significantly associated >4 months endocrine therapy were ESR1 (ERa, P ¼ 0.0005) and ERa targets IGFBP3 (P ¼ 1,5 Â 10 À4 ), PGR (P ¼ 0.008), and MYC (P ¼ 0.0055). However, only IGFBP3 was significant after correction for multiple comparisons (q ¼ 0.026; Fig. 4D ). IGFBP3 was previously described as E2-repressed in ovarian cancer (42) and we observed similar ERa regulation in our hormone-responsive models (Fig. 4E) . We did not see ERa regulation of IGFBP3 expression in OVCA432 cells (Supplementary Fig. S5 ). Using log-rank comparisons, the P value for the association with IGFBP3 and endocrine therapy was better than that of H-score (P ¼ 0.00002 vs. P ¼ 0.002; Fig. 4F In light of these data, we asked whether combining H-score with an aggregation of genes would provide stronger predictive power of time on endocrine therapy than a single gene. We used an SVM algorithm to identify features (genes and/or H-score) associated with duration of endocrine therapy. The top 30 features were significantly (P < 2 Â 10 À16 ) associated with endocrine response (Fig. 4H) , including H-score and IGFBP3 (Table 3 ). The majority of features were known ERa targets, suggesting that assessing ERa function might be a stronger predictor of time on endocrine treatment than ERa alone.
Discussion
Clinical trials of endocrine therapy suggest a subset of patients with ovarian cancer benefit from endocrine therapy. However, unlike for breast cancer, tumor ERa status (positive vs. negative) is not sufficient to predict response in HGSOC. Furthermore, linking ERa immunoscore with endocrine response in ovarian cancer has produced mixed results (13, 34, 38) . Implementing biomarkers that complement ERa will be critical to identifying appropriate patient populations for endocrine therapy.
Three studies have previously tried to identify biomarkers of endocrine response (34, 35, 43) , all utilizing a small panel of IHC markers. We pursued a comprehensive profile of potential biomarkers by designing and evaluating the EndoRx panel. Our analysis indicated lower IGFBP3 was significantly associated with prolonged duration of endocrine therapy (Fig. 4) , corroborating previous reports that IGFBP3 expression correlates with response to therapy (43, 44) . IGFBP3 expression was more strongly associated with time on therapy than H-score (Fig. 4) . Moreover, low IGFBP3 identified a subgroup of ERa low patients who received longer endocrine therapy. Given that IGFBP3 is ERa-suppressed (Fig. 4) (35) , our results suggest a direct output of ERa function better designates endocrine responsiveness than ERa itself. Further supporting this is the SVM analysis: while H-score was among the top features, it ranked 29th, indicating 28 genes, including ERa targets, carried stronger associations with endocrine response. Except IGFBP3, we did not find strong associations between previously reported biomarkers of endocrine response and outcomes in our cohort (34, 35, 43) . This could be attributable to different methodology (gene expression vs. IHC) or cohort size (ours is the largest to date). Although vimentin was shown to be associated with fulvestrant response (34) , difference in therapy may account for this discrepancy; independent classes of endocrine therapy may require different predictive markers.
Our EndoRx panel was designed on the basis of studies in models that recapitulate the varying endocrine response seen in clinical HGSOC. Consistent with previous reports that E2 promotes ovarian cancer cell growth (7, 8, 11) , PEO1 and PEO4 cells were endocrine responsive in 2D, 3D, and ULA cultures. While PEO1 and PEO4 cells were isolated from the same patient (9), they exhibited different E2-response phenotypes. We believe that this is attributable to the differences in cell line biology because the lines were isolated at different points in the patient's disease course. The PEO1 cells were isolated from her first recurrence, whereas the PEO4 cells were isolated from a later recurrence after the tumor became platinum-refractory.
In contrast to the E2-responsive PEO1 and PEO4 cells, OVCA432 and OVSAHO were E2-independent in 2D and 3D but became E2-responsive in ULA. None of our models expressed ERb, suggesting these effects are ERa-mediated and that ERa has unique roles throughout HGSOC progression. Elevated ERa protein in ULA supports the association between ERa levels and clinical endocrine response. Moreover, this alludes to a functional link between ERa protein levels and transcriptional activity. It is, however, also possible that a different E2-binding receptor is mediating these effects. Assessing the potential of other receptors as well as the tie between ERa function and ERa protein levels is an important direction for future investigation as it may provide insight into the efficacy of fulvestrant versus 4OHT. This also emphasizes the necessity of translational models such as PDXs and explants to fully understand ERa action in HGSOC.
We provide the first evidence of endocrine response in patientderived HGSOC models. Fulvestrant produced stronger effects on explant proliferation and gene expression than 4OHT, suggesting modality of endocrine therapy will be an important consideration in HGSOC treatment. Selective ERa modulators (e.g., 4OHT) exhibit partial agonism in certain tissues and cancers (27) whereas selective ER degraders (e.g., fulvestrant) are pure antagonists. Potential tamoxifen agonism in HGSOC has not been explored but tamoxifen exposure was reported to promote fallopian tube and ovarian lesions (45, 46) . Further comparisons of fulvestrant and 4OHT with other antiestrogens will be necessary to understand any differential class effects in HGSOC.
Our explant studies also suggest heterogeneous endocrine response across regions of HGSOC tumors: 4OHT and fulvestrant response varied in terms of both proliferation and gene expression between explants from the same PDX (Fig. 3) . It is possible that interactions between different regions would facilitate response of the bulk tumor. However, strategies for combination therapy should also be considered. Two such possibilities are MAPK and Src, which are known to crosstalk with ERa and drive endocrine resistance in ovarian cancer (47, 48) . Cotargeting PGR is also promising given its interaction with ERa (49) and recent reports demonstrating PGR agonists induce senescence in ovarian cancer cells (50) .
We focused our study on HGSOC as it is the most common clinical subtype of ovarian cancer. However, there is likely potential for endocrine therapy in endometrioid ovarian cancer as well, which is also frequently ERa-positive. Evaluating the role of ERa and IGFBP3 in this subtype is an important area for future investigation.
Our clinical analysis is somewhat limited by its retrospective nature. Modality of endocrine therapy and number of previous therapies vary across patients and inconsistent posttreatment data necessitate the use of surrogates for clinical responsiveness. Prospective studies with posttreatment specimen collection, standardized timing of endocrine therapy, and sufficient power to compare different endocrine agents will be necessary to solidify the utility of any biomarkers. In addition, the mechanistic role of these markers (e.g., IGFBP3) in ovarian cancer should be followed up in preclinical studies.
In summary, ERa modulates growth, survival, and gene expression in a subset of HGSOC and targeting ERa can be effective clinically. Inhibiting ERa with fulvestrant and 4OHT modulates expression of MYC, PGR, and IGFBP3 in HGSOC models. Moreover, expression of these genes reflects clinical endocrine response. Our findings may enable selection of HGSOC patients who would benefit from endocrine therapy. 
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